Skip to main content
. 2021 Jul 16;11(7):1045. doi: 10.3390/biom11071045

Figure 6.

Figure 6

Schematic representation of the main leptin peptide analogues with anti-tumor activity based on human leptin binding sites. LDFI is based on the sequence 39–42 (LDFI) of leptin binding site I; LPrA2 and IONP-LPrA2 are based on the amino acid sequence 70–95 of leptin binding site II; Allo-aca (H-alloThr-Glu-Nva-Val-Ala-Leu-Ser-ArgAca-NH2) and D-Ser (H-(D)Ser-Glu-Nva-Val-Ala-Leu-Ser-(N-Me)Arg-βAla-NH2) are based on the modified amino acid sequence 121–129 of leptin binding site III; OB3 is based on the amino acid sequence 116–122 of leptin binding site III.